Retinal Detachment
Also known as: Retinal, Retinae, Detached, Detachment
Methodology & AI Transparency ⓘ
Retinal Detachment Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain.
- 2 Real-world patient consensus: Diagnostic registry H33.20: Retinal Detachment is managed within Eyes & Vision (aka Retinal).
- 3 Typical cash cost range: Clinicians assessing Retinal Detachment focus on retinal pigment epithelium in Retinal Detachment (H33.20: oxidative drusen accumulation) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Retinal Detachment: maintaining Best-Corrected Visual Acuity in Retinal Detachment (H33.20: & OCT) within Intact retinal nerve fiber & macula (H33.20).
Ask our AI Specialists anything about Retinal Detachment
What Is Retinal Detachment?
The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. It provides the sharp, central vision needed for reading, driving, and seeing fine detail. A retinal detachment lifts or pulls the retina from its normal position. It can occur at any age, but it is more common in people over age 40. It affects men more than women and whites more than African Americans.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Retinal Detachment (H33.20) features retinal pigment epithelium in Retinal Detachment (H33.20: oxidative drusen accumulation). Cross-referenced with NIH MeSH (Retinal Detachment), therapeutic stabilization in eyes & vision is verified against HbA1c & Systemic in Retinal Detachment (H33.20: Blood Pressure).
Common Symptoms & Clinical Signs
- • Are extremely nearsighted
- • Have had a retinal detachment in the other eye
- • Presentation of Retinal Detachment (H33.20): gritty burning, foreign-body in Retinal Detachment (H33.20: sensation, reflex tearing,)
- • Secondary Retinal Detachment clinical sign: loss of peripheral in Retinal Detachment (H33.20: side vision)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Retinal Detachment Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H33.20 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Retinal Detachment (H33.20: & OCT) | Intact retinal nerve fiber & macula (H33.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Retinal Detachment (H33.20: Blood Pressure) | Microvascular retinal protection (H33.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Retinal Detachment H33.20] | 10 – 21 mmHg (individualized optic target) (H33.20) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Retinal Detachment
Treatment selection for Retinal Detachment depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Retinal Detachment)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
| New Insights on Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular: What a 1,097-Participant Study Found A greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution. Ophthalmology. Retina • 2022-11-15 • Phase III Randomized Trial | N = 1,097 | 90/100 | PMID 35654363 ↗ |
| Can This Approach Help? Inside the Latest Research on Semaglutide, central retinal thickness and continuous glucose monitoring in Semaglutide treatment did not impact CRT beyond what could be explained by changes in glycaemia. Journal of diabetes and its complications • 2025-06-15 • Randomized Controlled Trial | N = 30 | 88/100 | PMID 40239470 ↗ |
| Can This Approach Help? Inside the Latest Research on Resolution of outer retinal abnormalities in eyes with vitreomacular traction ELM disruption, EZ disruption and/or SRF are present in a significant percentage of eyes with VMT without MH. The British journal of ophthalmology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35288439 ↗ |
| Can This Approach Help? Inside the Latest Research on Retinal effects of 6 months of daily use of tadalafil or No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tadalafil or sildenafil for 6 months. Archives of ophthalmology (Chicago, Ill. : 1960) • 2009-04-15 • Randomized Controlled Trial | N = 82 | 88/100 | PMID 19365010 ↗ |
Retinal Detachment Patient Community & “People Like Me” Threads
Filter Retinal Detachment community threads and patient logs by age, biological sex, dosage, and treatment duration.